英文摘要 |
Metabolic dysfunction associated fatty liver (MAFLD) is the emergent and rapid growing liver disease. It has become the post common chronic liver disease worldwide including Taiwan. Simple steatosis or with mild inflammation is found in a large proportion of MAFLD patients, and steatohepatitis is found in only a small part of patients. Once steatohepatitis is developed, patients may progress to liver cirrhosis or hepatocellular carcinoma. The development and progression of MAFLD are the interactions of multiple risk factors including metabolic, environmental, genetic and epigenetic risk factors, and gut microbiota. However, the exact pathogenesis of MAFLD and contribution of each risk factor remain uncertain, and need further investigation to develop associated treatment for the outcome improvement. |